About Advanced Biomed Inc. Common Stock
https://www.advanbiomed.comAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan.
CEO
Yi Lu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public March 6, 2025
Method of going public IPO
Full time employees 40
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $7.67 M
52w High $4.10
52w Low $0.28
P/E -1.93
Volume 13.25K
Outstanding Shares 21.64M
About Advanced Biomed Inc. Common Stock
https://www.advanbiomed.comAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 ▼ | $523.91K ▲ | $-12.93K ▲ | 0% ▲ | $-0 ▲ | $-11.32K ▲ |
| Q4-2025 | $17.2K ▲ | $37.22K ▲ | $-22.74K ▲ | -132.22% ▼ | $-0 ▲ | $-20.66K ▲ |
| Q3-2025 | $0 | $20.81K ▲ | $-1.38M ▼ | 0% | $-0.07 ▼ | $-684.6K ▼ |
| Q2-2025 | $0 | $13.19K ▲ | $-907.9K ▼ | 0% | $-0.05 ▼ | $-426.66K ▼ |
| Q1-2025 | $0 | $12.93K | $-265.58K | 0% | $-0.01 | $-417.81K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $2.66M ▲ | $6.24M ▲ | $3.24M ▲ | $3M ▲ |
| Q4-2025 | $99.41K ▼ | $222.93K ▼ | $103.89K ▼ | $119.05K ▼ |
| Q3-2025 | $156.13K ▼ | $8.29M ▲ | $4.16M ▲ | $4.13M ▲ |
| Q2-2025 | $2.66M ▲ | $4.5M ▲ | $3.89M ▲ | $619.03K ▼ |
| Q1-2025 | $2.65M | $4.47M | $3.38M | $1.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-386.9K ▼ | $-20.39K ▲ | $-59.17 ▲ | $14.95K ▲ | $-12.25K ▲ | $-20.45K ▲ |
| Q4-2025 | $-22.74K ▲ | $-58.65K ▲ | $-676 ▲ | $-11.35K ▼ | $-56.73K ▼ | $-59.32K ▲ |
| Q3-2025 | $-42.08K ▲ | $-3.41M ▼ | $-2.21K ▼ | $5.9M ▲ | $2.53M ▲ | $-103.27K ▲ |
| Q2-2025 | $-907.9K ▼ | $-841.84K ▼ | $10.69K ▲ | $408.29K ▲ | $10.24K ▼ | $-831.15K ▼ |
| Q1-2025 | $-265.58K | $-29.68K | $-19.98K | $392.52K | $39.02K | $-49.66K |
CEO
Yi Lu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public March 6, 2025
Method of going public IPO
Full time employees 40
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0